US 11925629
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
granted A61KA61K31/443A61K31/4439
Quick answer
US patent 11925629 (Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer) held by Asana BioSciences, LLC expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Asana BioSciences, LLC
- Grant date
- Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/443, A61K31/4439, A61K31/444, A61K31/506